Novo Nordisk progression prospects drop after belcesiran terminated

Novo Nordisk’s belcesiran saw a 20-point decrease in its Phase Transition Success Rate (PTSR) in alpha-1 antitrypsin deficiency (A1AD) following the termination of a Phase II study. PTSR is the probability, given as a percentage, of a drug progressing successfully from one development stage to the next.